Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?

被引:43
作者
Drouet, Ludovic [1 ,2 ]
Sollier, Claire Bal Dit [1 ,2 ]
Steiner, Thorsten [3 ,4 ]
Purrucker, Jan [3 ]
机构
[1] Hop Lariboisiere, Paris, France
[2] Univ Paris 07, Paris, France
[3] Univ Heidelberg Hosp, Dept Neurol, Heidelberg, Germany
[4] Klinikum Frankfurt Hochst, Dept Neurol, Frankfurt, Germany
关键词
Non-vitamin K antagonist oral anticoagulants; administration and dosage; therapeutic use; coagulation testing; stroke; prevention; ISCHEMIC-STROKE PATIENTS; COAGULATION ASSAYS; BLEEDING COMPLICATIONS; LABORATORY MEASUREMENT; EMERGENCY MANAGEMENT; DABIGATRAN; WARFARIN; RIVAROXABAN; APIXABAN; EDOXABAN;
D O I
10.1177/1747493016659671
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Although the need for an emergency intervention may merit laboratory measurement of non-vitamin K antagonist oral anticoagulant (NOAC) concentration or anticoagulant activity, NOACs are not supposed to require routine monitoring due to their stable pharmacological profiles compared with warfarin. Aims To examine situations where NOAC measurement may be useful and to provide information about methodologies available to measure NOAC-related anticoagulation activity. Summary of review The routine coagulation tests, including prothrombin time, thrombin time, activated partial thromboplastin time, and international normalized ratio, have variable sensitivities to NOACs. Tests have been developed for use with specific NOACs, e.g. diluted thrombin time or chromogenic factor Xa assays. In emergency situations, such as severe bleeding, stroke, or a requirement for urgent surgery or procedures, there may be a need to assess anticoagulant activity to guide clinical decision making. In cases where neutralization of the anticoagulant effect is warranted, specific reversal agents are likely to become invaluable medical tools. Evidence to date suggests that dosing decisions for NOACs based on clinical features (e.g. age or renal function) can help optimize the benefit-risk balance without assessment of anticoagulant activity in non-emergency routine situations. Conclusions Regular monitoring of NOAC levels does not provide benefits and cannot be recommended at present. In some specific circumstances, e.g. severe bleeding, before urgent surgery, or before thrombolysis, measurement may be beneficial to assess whether a patient is actively anticoagulated. The availability of NOAC-specific reversal agents may change management practices in emergencies.
引用
收藏
页码:748 / 758
页数:11
相关论文
共 61 条
[21]   Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication [J].
Cuker, Adam .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (02) :241-247
[22]   Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review [J].
Cuker, Adam ;
Husseinzadeh, Holleh .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (03) :288-294
[23]   Conventional and near-patient tests of coagulation [J].
Curry, Andy N. G. ;
Pierce, J. M. Tom .
BJA EDUCATION, 2007, 7 (02) :45-50
[24]   Novel antidotes for target specific oral anticoagulants [J].
Das A. ;
Liu D. .
Experimental Hematology & Oncology, 4 (1)
[25]   Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure Substudy of the RE-LY trial [J].
Douketis, James D. ;
Healey, Jeff S. ;
Brueckmann, Martina ;
Eikelboom, John W. ;
Ezekowitz, Michael D. ;
Fraessdorf, Mandy ;
Noack, Herbert ;
Oldgren, Jonas ;
Reilly, Paul ;
Spyropoulos, Alex C. ;
Wallentin, Lars ;
Connolly, Stuart J. .
THROMBOSIS AND HAEMOSTASIS, 2015, 113 (03) :625-632
[26]   Perioperative Management of Antithrombotic Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines [J].
Douketis, James D. ;
Spyropoulos, Alex C. ;
Spencer, Frederick A. ;
Mayr, Michael ;
Jaffer, Amir K. ;
Eckman, Mark H. ;
Dunn, Andrew S. ;
Kunz, Regina .
CHEST, 2012, 141 (02) :E326S-E350S
[27]   Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants [J].
Ebner, Matthias ;
Peter, Andreas ;
Spencer, Charlotte ;
Haertig, Florian ;
Birschmann, Ingvild ;
Kuhn, Joachim ;
Wolf, Martin ;
Winter, Natalie ;
Russo, Francesca ;
Zuern, Christine S. ;
Blumenstock, Gunnar ;
Ziemann, Ulf ;
Poli, Sven .
STROKE, 2015, 46 (10) :2741-2747
[28]   Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants [J].
Faraoni, David ;
Levy, Jerrold H. ;
Albaladejo, Pierre ;
Samama, Charles-Marc .
CRITICAL CARE, 2015, 19
[29]   Edoxaban versus Warfarin in Patients with Atrial Fibrillation [J].
Giugliano, Robert P. ;
Ruff, Christian T. ;
Braunwald, Eugene ;
Murphy, Sabina A. ;
Wiviott, Stephen D. ;
Halperin, Jonathan L. ;
Waldo, Albert L. ;
Ezekowitz, Michael D. ;
Weitz, Jeffrey I. ;
Spinar, Jindrich ;
Ruzyllo, Witold ;
Ruda, Mikhail ;
Koretsune, Yukihiro ;
Betcher, Joshua ;
Shi, Minggao ;
Grip, Laura T. ;
Patel, Shirali P. ;
Patel, Indravadan ;
Hanyok, James J. ;
Mercuri, Michele ;
Vogelmann, O. ;
Gonzalez, C. ;
Ahuad Guerrero, R. ;
Rodriguez, M. ;
Albisu, J. ;
Rosales, E. ;
Allall, O. ;
Reguero, M. ;
Alvarez, C. ;
Garcia, M. ;
Ameriso, S. ;
Ameriso, P. ;
Amuchastegui, M. ;
Caceres, M. ;
Beloscar, J. ;
Petrucci, J. ;
Berli, M. ;
Budassi, N. ;
Valle, M. ;
Bustamante Labarta, G. ;
Saravia, M. ;
Caccavo, A. ;
Fracaro, V. ;
Cartasegna, L. ;
Novas, V. ;
Caruso, O. ;
Saa Zarandon, R. ;
Colombo, H. ;
Morandini, M. ;
Cuello, J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) :2093-2104
[30]   A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran [J].
Glund, Stephan ;
Moschetti, Viktoria ;
Norris, Stephen ;
Stangier, Joachim ;
Schmohl, Michael ;
van Ryn, Joanne ;
Lang, Benjamin ;
Ramael, Steven ;
Reilly, Paul .
THROMBOSIS AND HAEMOSTASIS, 2015, 113 (05) :943-951